Fluidigm Corp. (FLDM)

[Hole shot King]

Fluidigm (NASDAQ: $FLDM) is an industry-leading biotechnology tools provider with a vision to improve life through comprehensive health insight. We focus on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, and plant and animal research laboratories worldwide. Together with them, we strive to increase the quality of life for all.


http://investors.fluidigm.com/


Biopharma Update on the Novel Coronavirus: May 19

Diagnostics

The Centers for Disease Control and Prevention (CDC) is on the cusp of launching a massive, 25-city SARS-CoV-2 antibody study. Expected to launch in June or July, the study plans to test as many as 325,000 people to learn how the SARS-CoV-2 virus is spreading nationally, according to Reuters, reporting before the official announcement.

https://www.biospace.com/article/biopharma-update-on-the-novel-coronavirus-may-19/


Makes me think we have lots of news coming besides the



OU Medicine, University of Oklahoma Health Sciences Center and Oklahoma Medical Research Foundation File for FDA Emergency Use Authorization for COVID-19 Detection Test Utilizing Fluidigm Technology

http://investors.fluidigm.com/news-releases/news-release-details/ou-medicine-university-oklahoma-health-sciences-center-and




adding $FLDM